SEC Form 4 · accession 0001104659-26-076570
ArriVent BioPharma, Inc. · AVBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Merdad Parsey
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 22, 2026 · 9:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001868279
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $31.74 | Jun 18, 2026 | A | 13,562 | A | Jun 18, 2027 | Jun 17, 2036 | Common Stock | 13,562 | 13,562 | D |
Explanation of responses
- F1The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.